Logo
x

Search category

Subscribe Now

Marketing authorization

Enzene Receives Marketing Authorization for Romiplostim (biosimilar) in India

Enzene Receives Marketing Authorization for Romiplostim (biosimilar) in India

  • August 20, 2021
Biogen's Tysabri (natalizumab- SC) Receives EC's Marketing Authorization to Treat Relapsing-Remitting Multiple Sclerosis

Biogen's Tysabri (natalizumab- SC) Receives EC's Marketing Authorization to Treat Relapsing-Remitting Multiple Sclerosis

  • April 8, 2021
Bayer's Vitrakvi Receives MHLW's Approval for the Treatment of NTRK Fusion-Positive Advanced or Recurrent Solid Tumors

Bayer's Vitrakvi Receives MHLW's Approval for the Treatment of NTRK Fusion-Positive Advanced or Recurrent Solid Tumors

  • March 24, 2021
Enzene Receives Marketing Authorization for Teriparatide (biosimilar) in India

Enzene Receives Marketing Authorization for Teriparatide (biosimilar) in India

  • February 5, 2021
Celltrion Receives Health Canada's Approval for Remsima SC (biosimilar- infliximab) for Rheumatoid Arthritis

Celltrion Receives Health Canada's Approval for Remsima SC (biosimilar- infliximab) for Rheumatoid Arthritis

  • February 2, 2021
Biogen's Plegridy (peginterferon beta-1a- IM) Receives EC's Approval for Relapsing-Remitting MS

Biogen's Plegridy (peginterferon beta-1a- IM) Receives EC's Approval for Relapsing-Remitting MS

  • December 22, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.